Biography for Mark Hollmer
Mark Hollmer is a veteran life sciences journalist. Before joining FierceMarkets, he was a staff writer for "The Gray Sheet," an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. While there, he spoke regularly about top life sciences stories during appearances on New England Cable News, and commented on the growth of the Bay State's life sciences industry as part of a special that aired on the WGBH Boston public television station. Separately, he served a stint at Brown University, promoting innovations generated by the school's life sciences researchers and medical school. Mark lives with his partner in Washington, D.C. where he enjoys the region's multiple museums, great restaurants and excellent cultural scene.
Articles by Mark Hollmer
With an increasing reliance on nanoparticles to deliver intravenous drug treatments and serve as imaging agents, how do you make sure they are powerful enough to reach their target? The answer: math.
You've heard about China and India becoming increasingly significant locales in the Asia-Pacific region for conducting biotechnology research and drug development. Australia, not so much.
This year we're naming Fierce's 5 Drug Delivery Companies to Watch. All are making their mark by bringing drug delivery technology into everyday medical device and pharmaceutical use.
Israel's D. Medical Industries is shedding jobs, cutting salaries and restructuring in order to better focus on marketing its proprietary insulin pumps.
Another university is launching a scientific institute as a vehicle to seek a larger piece of the nanotechnology/drug delivery research funding pie.
May 13 is the do-or-die date for Marqibo, a nanoparticle-delivered injectable cancer drug conceived by Canada's Tekmira Pharamceuticals ($TKMR).
Bend Research plans to expand its drug delivery and manufacturing technology know-how into developing better biotherapeutics and vaccines.
After years of writing about companies with technology that stemmed from the mind of legendary MIT professor Robert Langer, I finally got to chat with him on the phone.
A cadre of U.K. researchers will begin a mid-stage trial later this month for a cystic fibrosis gene therapy delivered to the lungs with a nebulizer. They'll also begin a laboratory trial using a more advanced version of the same drug designed to ride in a modified virus to reach its target.
French drug delivery company Flamel Technologies ($FLML) is snatching up St. Louis-based Éclat Pharmaceuticals to access its specialty pharmaceutical and regulatory muscle for a planned expansion in the U.S. and elsewhere.